Pasvolsky, Oren
Yeshurun, Moshe
Fraser, Raphael
Estrada-Merly, Noel
Rozovski, Uri
Shargian-Alon, Liat http://orcid.org/0000-0002-6429-148X
Assal, Amer http://orcid.org/0000-0003-4707-9265
Banerjee, Rahul http://orcid.org/0000-0003-3781-5441
Bumma, Naresh
Gale, Robert Peter
Hagen, Patrick
Holmberg, Leona
Hossain, Nasheed M. http://orcid.org/0000-0002-3278-655X
Lazarus, Hillard M. http://orcid.org/0000-0002-1159-5607
Lee, Cindy
Mian, Hira http://orcid.org/0000-0003-1584-1067
Miller, Kevin C.
Nathan, Sunita http://orcid.org/0000-0001-7920-4265
Nagler, Arnon
Nishihori, Taiga http://orcid.org/0000-0002-2621-7924
Parrondo, Ricardo D.
Patel, Sagar http://orcid.org/0000-0001-9949-3615
Schroeder, Mark A. http://orcid.org/0000-0003-4924-8990
Usmani, Saad Z.
Wang, Trent http://orcid.org/0000-0001-5685-7204
Wirk, Baldeep http://orcid.org/0000-0002-2804-2531
Kumar, Shaji http://orcid.org/0000-0001-5392-9284
Shah, Nina
Qazilbash, Muzaffar H. http://orcid.org/0000-0003-2876-2886
D’Souza, Anita http://orcid.org/0000-0002-1092-5643
Article History
Received: 21 July 2021
Revised: 18 August 2021
Accepted: 26 August 2021
First Online: 4 October 2021
Competing interests
: Anita D’Souza reports institutional research funding from Sanofi, TeneoBio and Takeda; Consulting fees from Janssen; 2/2020-current. Rahul Banerjee reports grants or contracts from Pack Health to institution; consulting fees from SparkCures to self; and leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid to ASTCT Content Committee. Robert Peter Gale reports consulting fees with Kite Pharms, Inc., Fusion Pharma, LLC, C Stone Pharmaceuticals; and stock or stock options with Celgene Corporation. Leona Holmberg reports grants to self from Seattle Genetics, Sanofi, Millennium-Takada, Bristol Myers Squibb, Merck, Janssen; and royalties to Up-To-Date. Hillard M. Lazarus reports participation on a Data Safety Monitoring Board or Advisory Board with Bristol Myers Squibb/Celgene DSMB for CAR-T cell therapy in myeloma. Taiga Nishihori reports clinical trial support by Novartis to the institution; and drug supply by Karyopharm to the institution. Mark A. Schroeder reports consulting fees with Equillium Inc 2021; served on the speakers bureau and received honorary as a consultant for this work from Abbvie (May 2019), Merck (May 2019), Takeda (May 2019) and all speakers bureau service terminated in August 2019; and served on advisory boards and received honorary or consultant fees from Amgen (2017), Dova pharmaceuticals (May 2019), Dova pharmaceuticals (May 2019), FlatIron Inc (June 2019), GSK (October 2019), Gilead Sciences Inc., (~2017), Incyte (May 2018), Janssen (December 2020), Novo Nordisk (2018), Partner Therapeutics (November 2018), Pfizer (July 2018), and Sanofi Genzyme (December 2020). Saad Z. Usmani reports grants and/or personal fees from Amgen, Abbvie, BMS, Celgene, MundiPharma, Pharmacyclics, Sanofi, Seattle Genetics, Janssen, Takeda, SkylineDX, grants Merck, GSK, outside the submitted work. Shaji Kumar reports research support for clinical trials paid to institution form Abbvie, Celgene, Janssen, Takeda, Adaptive, KITE, Medimmune/Astra Zeneca, Merck, Novartis, Roche, Sanofi; research support for clincal trials paid to institution for past 36 months from Abbvie, Celgene, Janseen, Takeda, Adaptive, KITE, Medimmune/Astra Zeneca, Merck, Novartis, Roche and Sanofi; advisory board participation, paid to institution from Abbvie, Celgene, Janssen, Takeda, Adaptive, KITE, Medimmune/Astra Zeneca; and independent review committee from Oncopeptides. Muzaffar H. Qazilbash reports participation on advisory board from Oncopeptides and data safety monitoring board for Autolus. Nina Shah reports compensation for research funding from Celgene/BMS, Janssen, Bluebird Bio, Sutro Biopharma, Teneobio, Poseida, Nektar; Advisory role for GSK, Amgen, Indapta Therapeutics, Sanofi, CareDx, Kite, Karyopharm, Oncopeptides; and payments for research funding from Celgene/BMS, Janssen, Bluebird Bio, Sutro Biopharma, Teneobio, Poseida, Nektar.